| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3843145 | Actas Urológicas Españolas | 2014 | 7 Pages |
Abstract
Abiraterone is a pre-chemotherapy treatment option in selected patients with castration resistant metastatic prostate cancer, although it is necessary to improve the cost and to design more multicenter clinical trials to optimize the cost/benefit ratio.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
M. Arrabal-MartÃn, F. Anglada-Curado, J.M. Cózar-Olmo, J. Soler-MartÃnez, J. Moreno-Jiménez, J. Castiñeiras-Fernández, M.J. Ledo-Cepero, P. Beardo-Villar, M.J. Requena-Tapia, A. Zuluaga-Gómez, Grupo AAyEU Grupo AAyEU,